CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
NS-065/NCNP-01drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03167255
NCT03167255Phase 2Completed
CompareCT.gov

A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

NS Pharma, Inc.·interventional·Posted May 25, 2017·Updated Dec 28, 2022

In Brief

A Phase 2 clinical trial evaluating NS-065/NCNP-01 for Duchenne Muscular Dystrophy. Completed, enrolled 16 participants across 6 sites in 2 countries.

Detailed Summary

This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 192 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuchenne Muscular Dystrophy
CountriesCanada, United States
CollaboratorsNippon Shinyaku Co., Ltd., Cooperative International Neuromuscular Research Group, Therapeutic Research in Neuromuscular Disorders Solutions

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 25, 2017
Enrollment StartJul 6, 2017
Primary CompletionOct 20, 2021
Study CompletionNov 15, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.1 years ago

Interventions

NS-065/NCNP-01drug

Received during weekly intravenous infusions